javier cortes, asco20: key findings of the keynote-355 study
Published 4 years ago • 218 plays • Length 7:09Download video MP4
Download video MP3
Similar videos
-
5:37
researcher comment: the keynote-355 trial | javier cortes
-
4:53
chemoimmunotherapy in tnbc: the keynote-355 trial
-
4:49
keynote-355: pembro chemo in triple-negative breast cancer
-
22:13
part 2 - management of triple-negative metastatic breast cancer - dr. javier cortes, barcelona
-
1:30
keynote-355: hrqol unaffected by the addition of pembrolizumab to chemotherapy for tnbc
-
43:41
revolutionising triple negative breast cancer treatment
-
41:32
neoadjuvant prostate cancer clinical trials: advancing care and science
-
9:43
week 16: 8th chemo done of taxol, carbo, & keytruda
-
2:34
esmo 2021 breast cancer highlights: tulip and keynote-355
-
3:18
#esmo21 highlights on combination of pembrolizumab plus chemotherapy in mtnbc: the keynote-355 study
-
2:07
keynote-355: pembrolizumab in triple-negative breast cancer
-
4:54
hope rugo, md, shares the design and outcomes of keynote-355 presented at sabcs 2020
-
0:53
keynote-522 demonstrates potential for immunotherapy in triple-negative breast cancer
-
4:11
asco 2020: pembrolizumab plus chemotherapy for patients with metastatic triple-negative breast c...
-
12:45
keynote-355: first-line pembrolizumab plus chemotherapy for metastatic triple-negative breast ca...
-
2:24
keynote-355: pembrolizumab in triple-negative breast cancer
-
9:59
gs1-01: "phase 3 study of pembrolizumab chemotherapy vs placebo chemotherapy as neoadjuvant..."
-
0:43
management of residual disease in triple negative breast cancer
-
3:05
esmo 2020 highlights on sacituzumab govitecan in metastatic tnbc: the ascent study
-
2:36
keytruda plus chemotherapy improves progression-free survival in metastatic breast cancer
-
0:50
update on keynote 522, the current standard of care for triple negative breast cancer.
-
0:57
a post hoc analysis of adjuvant radiation therapy in the keynote-522 study